Bilateral inflammatory breast cancer treated with pembrolizumab and surgery

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Bilateral breast cancers had different biology: right side ER/PR-positive and HER2 FISH-negative; left side triple-negative/HER2 1+.

As of March 2025, she had no recurrence 6 months after bilateral mastectomy, bilateral axillary lymph node dissection, thoracoabdominal flap closure, and planned postmastectomy radiation for Stage IIIC bilateral inflammatory breast cancer.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer With Severe Myelitis During Pembrolizumab Treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-negative, PR-negative, HER2-negative, germline PALB2 variation

Imaging showed a complete tumor response before surgery, and surgery 6 months later found no residual breast cancer or involved sentinel nodes.

PubMed CentralRead more →

Triple-Negative Breast Cancer and Urgent Fertility Preservation Before Chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative, PR-negative, HER2-negative, triple negative

Chemotherapy had started, and the breast-cancer treatment course was still ongoing.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Maggie's Survivor Story

Patient Info: Maggie, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lungs, lymph nodes; possible liver

Diagnosed in 2022 with de novo Stage IV triple-negative breast cancer involving the lungs and lymph nodes, with possible liver involvement. After entering a chemotherapy/immunotherapy clinical trial, she reported being cancer-free / no evidence of disease for well over 1 year as of February 2025.

The Patient StoryRead more →

Facing Triple-Negative Breast Cancer: Chance’s Story

Patient Info: Chance, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of February 2025, Chance described follow-up after Stage II BRCA1-associated triple-negative breast cancer and stated that she did not currently have cancer, while continuing close surveillance.

The Patient StoryRead more →

Stage III Triple-Negative Breast Cancer: Kelly's Survivor Story

Patient Info: Kelly, Female, Under 40 | Stage III

Biomarkers: Triple-negative breast cancer; no inherited cancer gene mutation found.

As of February 2025, Kelly identified as a Stage IIIC triple-negative breast cancer survivor after neoadjuvant chemotherapy, double mastectomy with reconstruction, and radiation, and was using her experience to support others through TNBC Thrivers.

The Patient StoryRead more →

Stage IIIC triple-negative breast cancer with pembrolizumab-related HLH/DIC and pathologic complete response

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative/HR-negative breast cancer with germline BRCA1 pathogenic mutation. HLH/DIC episode had high IL-6

Surgery confirmed ypT0ypN0 pathologic complete response after neoadjuvant carboplatin, paclitaxel, and pembrolizumab, and she remained recurrence-free while being monitored without additional cancer-directed treatment.

PubMed CentralRead more →

Stage I triple-negative solid basaloid adenoid cystic breast cancer treated with mastectomy and oral chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Current tumor was triple-negative with high Ki-67 and c-kit/CK7 staining. Prior breast cancer was ER-positive, HER2-positive, PR-negative.

One year after mastectomy and postoperative tegafur-gimeracil-oteracil potassium, she was recovering well without signs of metastasis.

PubMed CentralRead more →

Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Marissa's Survivor Story

Patient Info: Marissa Sweitzer, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative; no breast cancer genetic mutation reported

As of December 2024, Marissa had a complete response to treatment and no evidence of cancer after postpartum triple-negative breast cancer involving the breast and lymph nodes was treated with chemotherapy, double mastectomy and 5 weeks of radiation.

Cleveland ClinicRead more →

Deltra: Stage IV Breast Cancer

Patient Info: Deltra James, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

As of December 2024, Deltra James was living with de novo Stage IV triple-negative metastatic breast cancer and advocating for sexual-health and intimacy conversations in metastatic care.

Triple-Negative Breast Cancer: Juliette's Survivor Story

Patient Info: Juliette Landgrave, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

After egg preservation, 16 rounds of chemotherapy with complete response, lumpectomy, 25 radiation sessions and 1 year of immunotherapy, Juliette was cancer-free as of December 2024.

City of HopeRead more →

Breast Cancer Recurrence in the Small Intestine and Bone More Than 5 Years After Diagnosis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial ER-positive, PR-positive, HER2-negative; metastatic lesion ER-negative, PR-negative, triple negative

Metastatic Site: small intestine, bone, right fallopian tube

More than 5 years after her December 2018 diagnosis, she was alive at 1-year follow-up after metastatic recurrence, with multiple bone metastases still present.

PubMed CentralRead more →

Rare squamous cell breast cancer: tumorectomy and partial mastectomy

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 21%, triple negative

As of August 2024, she had no recurrence 4 years after surgery, adjuvant AC/docetaxel chemotherapy, and residual breast irradiation for Stage I squamous cell carcinoma of the breast arising in a benign phyllodes tumor.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Deltra's Patient Story

Patient Info: Deltra James, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

As of November 2024, Deltra James was living with de novo Stage IV triple-negative metastatic breast cancer and discussing dating, confidence, and emotional safety after diagnosis.

Secretory breast carcinoma: mastectomy, surveillance, no recurrence at 2 years

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative; PR-negative; HER2-negative

No local recurrence or metastasis after 2 years of follow-up after right mastectomy and axillary lymph-node dissection for triple-negative secretory breast carcinoma.

PubMed CentralRead more →

Triple-Negative Breast Cancer in a Young Woman With Bloom Syndrome Followed by Myelodysplastic Syndrome

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative

Follow-up imaging after breast-cancer treatment showed no malignant lesions. Eight months after treatment, she developed myelodysplastic syndrome with excess blasts and later died from sepsis at age 33.

PubMed CentralRead more →

HR-Positive Breast Cancer: Anna's Survivor Story

Patient Info: Anna, Female, Under 40

Biomarkers: ER-positive; PR-positive; HER2-positive

As of October 2024, Anna was about 7 years from diagnosis and described long-term survivorship after surgery, chemotherapy, radiation, biologic treatment, and tamoxifen-related mental-health effects.

The Patient StoryRead more →

Anna’s Triple-Positive Breast Cancer Story

Patient Info: Anna, Female, Under 40

Biomarkers: ER-positive, PR-positive and HER2-positive

Anna completed surgery, chemotherapy and radiation and continued to navigate the effects of hormone therapy, early menopause and fertility loss.

The Patient StoryRead more →

Stage II Triple-Negative Breast Cancer: Italia's Survivor Story

Patient Info: Italia Russell, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA mutation

As of October 2024, Italia had no evidence of disease after Stage II triple-negative breast cancer responded to chemotherapy, the tumor was gone by double mastectomy, and she was completing immunotherapy with 3 infusions left.

Cleveland ClinicRead more →

Triple-negative breast cancer in remission after chemotherapy and pembrolizumab

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-negative; PR-negative; HER2-negative

Triple-negative breast cancer was in remission, with PET-CT showing no new primary or secondary tumors, while pembrolizumab-related adrenal insufficiency required ongoing endocrine management.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Erica's Survivor Story

Patient Info: Erica Watson, Female, 50s

Biomarkers: ER-negative; PR-negative; HER2-negative

As of October 2024, Erica had no evidence of disease after triple-negative breast cancer showed a complete response to 16 chemotherapy treatments, lumpectomy, reconstructive surgery and 15 rounds of radiation.

Cleveland ClinicRead more →

Melissa Berry Deltra: Stage IV Breast Cancer

Patient Info: Deltra James, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

As of September 2024, Deltra James was living with de novo Stage IV triple-negative metastatic breast cancer and advocating for confidence and intimacy while living with advanced disease.

Triple-negative breast cancer: partial response to TAC chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Triple-negative breast cancer with EGFR positivity and high Ki-67; BRCA1 staining was positive by IHC.

After 1 cycle of TAC chemotherapy, the large ulcerated breast tumor shrank enough for surgery. Radical mastectomy with adjacent flap transfer achieved clear margins and no nodal metastatic cancer; she was recovering at home while awaiting planned postoperative AC-T chemotherapy.

PubMed CentralRead more →